查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095373

新冠病毒檢測市場－2026-2032年全球市場預測

COVID-19 Testing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，COVID-19 檢測市場規模將達到 231.5 億美元，複合年成長率為 2.96%。

主要市場統計數據
基準年 2025 188.7億美元
預計年份：2026年 194.2億美元
預測年份 2032 231.5億美元
複合年成長率 (%) 2.96%

新冠病毒檢測執行摘要

新冠病毒檢測仍然是感染疾病監測、臨床分診、疫情應變和公共衛生準備的關鍵要素。檢測生態系包括分子診斷（例如RT-PCR和核酸增幅檢查）、快速抗原檢測、血清學檢測、檢體採集系統、檢查室資訊工作流程以及日益普及的分散式即時檢測模式。需求趨勢正從大規模緊急篩檢計畫轉向針對有症狀個體、高風險環境、旅行和職場的必要檢測、醫院篩檢、變異株監測以及區分SARS-CoV-2與流感、呼吸道合胞病毒（RSV）和其他呼吸道病原體的綜合呼吸道檢測。監管機構和公共衛生部門繼續優先考慮檢測的準確性、反應時間、可及性、基因組監測的整合以及跨檢查室和分散式醫療環境的品管。隨著新冠病毒成為持續呼吸道疾病管理的重要組成部分，行業相關人員正在優先考慮彈性供應鏈、檢查室操作自動化、數位化報告、多種檢測方法的開發以及公平獲取可靠診斷服務。

新冠病毒檢測環境的變革性變化

新冠病毒檢測模式已從被動的緊急部署轉變為更結構化、以監測主導且與臨床緊密結合的模式。在疫情急性期，公共衛生系統擴大了高通量PCR檢測能力、緊急使用授權流程、免下車檢測、居家檢體採集以及快速抗原檢測套組的分發。目前的特點是採取選擇性檢測策略、提升檢查室準備水平，並更廣泛地使用多種呼吸道診斷方法來支持季節性感染高峰期的臨床決策。一個重大轉變是從單一SARS-CoV-2檢測轉向針對特定症候群的檢測，後者可以從單一檢體中識別多種呼吸道病原體，從而改善治療策略、感染控制和合理使用抗生素。分散式檢查也日趨成熟，即時檢測和居家檢測在快速風險評估中發揮著至關重要的作用，但在臨床、流行病學和危急情況下，檢查室檢測對於確診仍然至關重要。同時，基因測序和變異監測繼續為疫苗株的選擇、公共衛生指南和疫情風險評估提供資訊。這種情況越來越受到品質保證、報銷政策、資料互通性以及在疫情爆發前保持診斷能力的能力的影響，以避免疫情初期供不應求時出現的效率低下問題。

人工智慧對新冠病毒檢測的累積影響

人工智慧 (AI) 透過最佳化工作流程、輔助解讀檢測結果、預測需求、進行基因組監測和進行公共衛生分析，對新冠病毒檢測產生日益顯著的影響。在檢查室環境中，AI 系統可以幫助確定檢體優先順序、發現操作瓶頸、提高設備利用率，並透過識別異常結果模式和潛在的流程偏差來支援品管。在臨床環境中，機器學習模型可以整合症狀、暴露史、影像學觀察、疫苗接種情況和檢測結果，以輔助分診和檢測決策；然而，這些工具需要經過仔細檢驗，以避免偏差和不恰當的臨床依賴。 AI 在基因組流行病學中也發揮著重要作用，演算法可以幫助識別新的變異株、追蹤突變模式，並將定序資料與流行病學訊號關聯起來。在分散式檢查和居家檢測中，AI 行動應用程式可以改善使用說明、記錄檢測結果、確保報告合規性並與醫療保健系統整合。然而，AI 的累積效應取決於安全的資料管治、透明的模型檢驗、與公共衛生系統的互通性以及對臨床決策支援的監管要求的遵守情況。短期來看，其最大價值在於「補充」而非「取代」檢驗的診斷流程。在面臨營運壓力的情況下，例如檢測量大、呼吸系統檢測項目複雜且需要快速報告時，這種價值尤其明顯。

關於新冠病毒檢測的關鍵區域見解

亞太地區在新冠病毒檢測中繼續發揮核心作用，這得益於其高都市區密度、大規模的診斷試劑和耗材製造地，以及中國、印度、日本、韓國和澳洲等國強大的公共衛生監測能力。該地區廣泛應用PCR檢測、快速抗原檢測、數位健康報告以及污水和基因組監測，目前的重點工作包括多參數呼吸道檢測、應對需求激增的能力以及為未來疫情爆發做好準備。歐洲擁有成熟的診斷環境，這得益於公共衛生合作、檢查室認證、國家標準實驗室和變異監測，並日益重視綜合呼吸道疾病監測、跨境健康安全以及醫療保健系統間品質標準的協調統一。北美的特點是擁有先進的分子診斷基礎設施、廣泛的檢查室網路、法律規範、高普及率的居家和即時檢測，並持續重視呼吸道病毒鑑別、醫院檢測流程、污水監測、基因測序和公共衛生數據合作。在拉丁美洲，自疫情爆發以來，檢查室能力得到加強，巴西和墨西哥已成為診斷、公共衛生檢測和基因測序活動的重要樞紐。然而，地域差異、保險報銷限制和物流挑戰仍然影響著檢測的可及性。在非洲，分子偵測能力透過疫情期間的投資和區域實驗室網路擴展，但基礎設施不均衡、人力資源限制、供應鏈依賴和可及性差異仍然是重大挑戰。同時，加強監測網路和病原體基因組分析工作提高了應對新冠肺炎和其他新興感染疾病的準備程度。在中東，疫情初期就對現代化檢查室基礎設施、機場和旅行相關篩檢能力以及醫療衛生系統的數位化進行了投資。同時，目前的檢測策略也越來越與醫院的感染控制、高流動性族群的管理以及集體爆發的防範措施相協調。

新冠病毒檢測的關鍵群體分析

北約成員國主要透過安全合作合作，但它們在部隊戰備、生物安全、醫療物流、部署人員健康以及行動連續性等方面共用的戰略關切。可靠的新冠病毒檢測和更廣泛的呼吸道病原體檢測對於保護軍事醫療系統和關鍵基礎設施至關重要。七國集團（G7）國家普遍擁有先進的檢查室自動化、完善的監管流程、報銷機制、公共衛生定序能力以及較高的分子和多重檢測普及率，並重點關注疫情防範、儲備策略、數據互通性和高風險人群保護。金磚國家由於人口眾多、醫療保健資源分佈不均、國內診斷設備製造能力有限以及在全球公共衛生監測中發揮著重要作用，其檢測系統整體上呈現出相當大的複雜性。優先事項包括可負擔性、擴充性、定序能力、分散式診斷和彈性供應鏈。歐盟受益於協調的法規結構、疾病監測機制、檢查室網路和跨境衛生安全合作，從而能夠在檢測檢驗、變異株追蹤、呼吸道感染疾病監測和緊急準備規劃方面開展更強力的合作。東南亞國協市場在新冠病毒檢測成熟度方面呈現多樣化的格局，從高度數位化的公共衛生系統到仍將分散式檢測和檢查室擴建作為優先事項的環境，不一而足。該地區在邊境管控、社區檢測和本地化生產方面的經驗，激發了人們對價格合理、快速檢測、多參數呼吸道診斷以及穩健採購系統的需求。海灣合作理事會（GCC）成員國擁有先進的醫療基礎設施、強大的投資能力以及廣泛的數位醫療應用，這為先進的檢測、即時檢測部署、快速公共衛生響應能力以及針對流動人口、勞動力和旅行者的客製化檢測策略提供了支持。

各國新冠病毒檢測情況的關鍵訊息

中國憑藉其大規模的檢測經驗和龐大的診斷試劑生產能力，在疫情監測、呼吸道病原體監測和供應鏈韌性方面繼續發揮至關重要的作用。美國擁有最先進的新冠病毒檢測體系之一，背後有大規模的臨床實驗室網路、廣泛的居家抗原檢測、醫院分子檢測、公共衛生監測、污水監測和基因測序能力的支持。日本在老齡化社會中強調高品質的診斷、以醫院為中心的檢測以及呼吸道感染疾病監測。同時，印度正在擴大其國內診斷試劑生產能力，發展分子檢測網路，並增加即時檢測的可及性，以滿足其龐大人口的需求，但農村地區的覆蓋範圍和可負擔性仍然是重大挑戰。德國受益於其完善的臨床實驗室基礎設施、高品質的分子診斷和強大的臨床實驗室網路。英國憑藉其在疫情期間累積的豐富檢測經驗和強大的基因組監測專業知識，正日益重視標靶檢測和綜合呼吸道監測。澳洲在公共衛生實驗室間合作、邊境檢疫經驗和綜合呼吸道監測方面具有優勢；法國則擁有完善的公共衛生和醫院檢測體系，並專注於品質監測、感染控制和診斷。韓國因其快速的診斷部署、數位化報告、高效的公共衛生應對基礎設施以及對新冠病毒和其他新發呼吸道病原體的持續應對準備而備受讚譽。義大利和西班牙在疫情初期遭受重創，已加強了檢測網路和監測方法，並繼續優先進行醫院檢測、呼吸道疾病的鑑別診斷以及保護弱勢群體。加拿大強調協調的公共衛生檢測、檢查室品管系統和呼吸道病毒監測，但各省之間的差異影響了檢測的可近性和優先順序。俄羅斯繼續專注於國內檢測能力和感染疾病監測，並擁有大規模的國家級檢測能力和公共衛生檢測基礎設施。巴西仍然是拉丁美洲領先的檢測中心，擁有公共衛生實驗室、學術定序計畫和私人診斷實驗室的支持，但區域差異影響了檢測服務的可近性。自疫情爆發以來，墨西哥擴大了檢測能力，公共和私人檢測管道支援臨床診斷和監測，儘管不同地區的檢測機會有所不同。

為行業領導者提供的實用建議

產業領導者應優先考慮具有彈性、品質有保障的檢測平台，這些平台能夠在常規呼吸道疾病診斷和緊急應變之間靈活切換。產品策略應著重於臨床實用的多項檢測、簡化的即時檢測流程、可靠的居家檢測支援以及與數位化報告系統的兼容性。實驗室和醫療機構應投資於自動化、人才培養、生物安全和互通資訊系統，以縮短報告時間並加強監測報告機制。診斷測試開發商應保持嚴格的分析和臨床檢驗，特別是針對新變種和多參數檢測組合，並適應不斷變化的監管要求。公部門和私部門的相關人員應實現試劑、拭子、塑膠製品、對照品和設備的供應商多元化，以降低供應中斷的風險。領導者還需要加強與公共衛生機構、醫院、藥局和社區醫療組織的合作，以改善服務不足人口的就醫途徑。符合倫理的人工智慧實施、網路安全、病患隱私保護和透明的資料管治應融入數位檢測流程。最重要的是，各組織不應將 COVID-19 檢測視為疫情時代一個單獨的產品類型，而應將其視為應對呼吸道疾病的更廣泛策略的一部分。

調查方法

本執行摘要採用系統性的二手研究途徑編寫，參考了經檢驗的公共衛生、監管、科學和產業相關資訊來源。該調查方法強調來自國家和地區公共衛生機構、世界衛生組織、同行評審的醫學文獻、監管指南、臨床實驗室醫學標準、當前臨床診斷實踐趨勢以及實驗室部署、監測和技術應用的記錄趨勢的證據。透過檢視檢測方法的演變、監管變化、臨床效用、檢查室營運、區域醫療保健系統能力、基因組監測活動、供應鏈韌性、污水監測、即時檢測部署以及與數位醫療的整合，整合了相關見解。本檢驗避免使用未經驗證的預測，也不依賴市場規模、市場佔有率或預測數據。透過公開可驗證的指標，檢驗區域、群體和國家層面的具體見解，這些指標包括醫療保健基礎設施、檢測政策的演變、診斷服務的可及性、公共衛生監測能力、監管成熟度和疫情應對準備。本研究過程採用交叉檢驗，利用多個可靠資訊來源，以確保結果的一致性、相關性以及數據驅動的解讀，從而為 COVID-19 檢測的策略決策提供支援。

結論

新冠病毒檢測已從大規模緊急篩檢發展成為呼吸道疾病管理、集體爆發防治和公共衛生監測的重要支柱。持續的SARS-CoV-2疫情、保護高危險群的必要性、區分新冠病毒與流感和呼吸道合胞病毒（RSV）的臨床價值以及變異株監測的重要性，都凸顯了該領域長期的重要性。最重要的機會包括多參數檢測、分散式檢測、檢查室、人工智慧驅動的工作流程支援以及可互通的數位化報告。同時，相關人員必須應對成本效益、品質保證、合規性、公平取得和供應鏈韌性等挑戰。將新冠病毒診斷整合到更廣泛的感染疾病控制策略中的機構，將更有能力在季節性疫情、局部疫情和未來的公共衛生突發事件中為醫療衛生系統提供支援。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：新冠病毒檢測市場：依檢測類型分類

  • 分子檢測
    • 單一標靶RT-PCR
    • 多重RT-PCR
    • 等溫擴增試驗
  • 抗原檢測
    • 檢查室抗原檢測
    • 家用抗原檢測
  • 血清學檢測

第8章：新冠病毒檢測市場：依樣本類型分類

  • 上呼吸道檢體
    • 鼻咽拭子
    • 口腔和咽拭子
    • 前鼻腔拭子
  • 下呼吸道檢體
    • 痰
    • 支氣管肺泡灌洗液
    • 氣管抽吸物
  • 唾液檢體
  • 血液和血漿檢體

第9章：新冠病毒檢測市場：依產品類型分類

  • 檢測套組和試劑
    • 分子檢測套組
    • 抗原檢測套組
    • 血清學檢測套組
    • 控制和校準器
    • 樣品製備試劑
  • 服務
    • 檢查服務
    • 外包測試服務
    • 數據分析和報告服務

第10章：新冠病毒檢測市場：依最終用戶分類

  • 醫院和診所
    • 急診醫院
    • 專科醫院
    • 門診部
  • 診斷檢查室
    • 獨立檢測實驗室
    • 醫院檢查室
  • 診所
  • 學術研究機構

第11章：新冠病毒檢測市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第12章：新冠病毒檢測市場：依群體分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第13章：新冠病毒偵測市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • 1DROP Diagnostics
  • Abbott Laboratories
  • ADT Biotech Sdn Bhd
  • Aldatu Biosciences
  • altona Diagnostics GmbH
  • Avellino Lab USA, Inc.
  • bioMerieux SA
  • Co-Diagnostics, Inc.
  • Curetis GmbH
  • Danaher Corporations
  • F. Hoffmann-La Roche AG
  • GenMark Diagnostics, Inc.
  • Hologic, Inc.
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Mylab Discovery Solutions Pvt. Ltd.
  • Perkin Elmer, Inc.
  • Quidel Corporation
  • Randox Laboratories Ltd.
  • SD Biosensor, Inc.
  • Seegene, Inc.
  • Shenzhen Bioeasy Biotechnology Co., Ltd.
  • Siemens Healthineers AG
  • SolGent Co.,Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-02026C4C986E

The COVID-19 Testing Market is projected to grow by USD 23.15 billion at a CAGR of 2.96% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.87 billion
Estimated Year [2026] USD 19.42 billion
Forecast Year [2032] USD 23.15 billion
CAGR (%) 2.96%

COVID-19 Testing Executive Summary

COVID-19 testing remains a critical component of infectious disease surveillance, clinical triage, outbreak response, and public health preparedness. The testing ecosystem includes molecular diagnostics such as RT-PCR and nucleic acid amplification tests, rapid antigen tests, serology assays, sample collection systems, laboratory information workflows, and increasingly decentralized point-of-care testing models. Demand patterns have evolved from emergency mass-screening programs toward targeted testing for symptomatic individuals, high-risk settings, travel and workplace protocols where applicable, hospital admission screening, variant monitoring, and integrated respiratory testing panels that differentiate SARS-CoV-2 from influenza, RSV, and other respiratory pathogens. Regulatory agencies and public health authorities continue to emphasize test accuracy, turnaround time, accessibility, genomic surveillance integration, and quality management across laboratories and decentralized care environments. As COVID-19 becomes part of ongoing respiratory disease management, industry stakeholders are prioritizing resilient supply chains, automated laboratory operations, digital reporting, multiplex assay development, and equitable access to reliable diagnostics.

Transformative Shifts in the COVID-19 Testing Landscape

The COVID-19 testing landscape has shifted from reactive emergency deployment to a more structured, surveillance-led, and clinically integrated model. During the acute pandemic phase, public health systems expanded high-throughput PCR capacity, emergency-use authorization pathways, drive-through testing, home sample collection, and rapid antigen distribution. The current environment is characterized by selective testing strategies, stronger laboratory preparedness, and broader use of multiplex respiratory diagnostics to support clinical decision-making during seasonal infection surges. A major transformation is the move from standalone SARS-CoV-2 testing toward syndromic panels that can identify multiple respiratory pathogens from a single sample, improving treatment decisions, infection control, and antimicrobial stewardship. Decentralized testing has also matured, with point-of-care and at-home formats playing an important role in rapid risk assessment, although confirmatory laboratory testing remains important in clinical, epidemiological, and high-consequence settings. Meanwhile, genomic sequencing and variant surveillance continue to inform vaccine strain selection, public health guidance, and outbreak risk assessment. The landscape is increasingly shaped by quality assurance, reimbursement policy, data interoperability, and the ability to maintain surge-ready diagnostic capacity without the inefficiencies seen during early pandemic supply shortages.

Cumulative Impact of Artificial Intelligence on COVID-19 Testing

Artificial intelligence is increasingly influencing COVID-19 testing through workflow optimization, assay interpretation support, demand planning, genomic surveillance, and public health analytics. In laboratory environments, AI-enabled systems can help prioritize samples, detect operational bottlenecks, improve instrument utilization, and support quality control by identifying unusual result patterns or potential process deviations. In clinical settings, machine learning models can combine symptoms, exposure history, imaging findings, vaccination status, and laboratory results to support triage and testing decisions, although such tools require careful validation to avoid bias and inappropriate clinical reliance. AI is also valuable in genomic epidemiology, where algorithms assist in identifying emerging variants, tracking mutation patterns, and linking sequencing data with epidemiological signals. For decentralized and at-home testing, AI-supported mobile applications may improve instructions for use, result capture, reporting compliance, and linkage to care. However, the cumulative impact of AI depends on secure data governance, transparent model validation, interoperability with public health systems, and adherence to regulatory expectations for clinical decision support. The strongest near-term value lies in augmenting, not replacing, validated diagnostic workflows, especially where high testing volumes, complex respiratory panels, and rapid reporting requirements create operational pressure.

Key Regional Insights for COVID-19 Testing

Asia-Pacific continues to be central to COVID-19 testing due to its dense urban populations, large diagnostics and consumables manufacturing base, and strong public health surveillance capabilities in countries such as China, India, Japan, South Korea, and Australia. The region has demonstrated extensive use of PCR testing, rapid antigen programs, digital health reporting, and wastewater and genomic surveillance, while current priorities include multiplex respiratory testing, surge readiness, and preparedness for future outbreaks. Europe has a mature diagnostics environment supported by public health coordination, laboratory accreditation, national reference laboratories, and variant monitoring, with increasing attention to integrated respiratory disease surveillance, cross-border health security, and harmonized quality expectations across health systems. North America is characterized by advanced molecular diagnostics infrastructure, broad laboratory networks, regulatory oversight, high adoption of home and point-of-care testing, and ongoing emphasis on respiratory virus differentiation, hospital testing protocols, wastewater monitoring, genomic sequencing, and public health data connectivity. Latin America has strengthened laboratory capacity since the pandemic, with Brazil and Mexico serving as important anchors for diagnostic access, public health testing, and sequencing activity, although geographic disparities, reimbursement constraints, and logistics continue to influence test availability. Africa has expanded molecular testing capacity through pandemic-era investments and regional laboratory networks, but uneven infrastructure, workforce limitations, supply chain dependence, and access gaps remain important considerations; at the same time, strengthened surveillance networks and pathogen genomics initiatives are improving readiness for COVID-19 and other emerging infectious diseases. The Middle East has invested in modern laboratory infrastructure, airport and travel-related screening capabilities during earlier pandemic phases, and health system digitization, while current testing strategies are increasingly aligned with hospital infection control, high-mobility population management, and outbreak preparedness.

Key Group Insights for COVID-19 Testing

NATO countries, while aligned primarily through security cooperation, share strategic concerns related to force readiness, biosecurity, medical logistics, deployed personnel health, and continuity of operations, making reliable COVID-19 testing and broader respiratory pathogen detection relevant for military health systems and critical infrastructure protection. G7 countries typically demonstrate advanced laboratory automation, established regulatory pathways, reimbursement mechanisms, public health sequencing capacity, and high adoption of molecular and multiplex testing, with emphasis on pandemic preparedness, stockpiling strategies, data interoperability, and protection of high-risk populations. BRICS countries collectively represent substantial testing complexity due to large populations, varied healthcare access, domestic diagnostic manufacturing capabilities, and significant roles in global public health surveillance; priorities include affordability, scalability, sequencing capacity, decentralized diagnostics, and resilient supply chains. The European Union benefits from coordinated regulatory frameworks, disease surveillance mechanisms, laboratory networks, and cross-border health security cooperation, enabling stronger alignment in test validation, variant tracking, respiratory infection monitoring, and preparedness planning. ASEAN markets reflect diverse COVID-19 testing maturity, ranging from highly digitized public health systems to settings where decentralized access and laboratory expansion remain priorities; the group's experience with border controls, community testing, and regional manufacturing has increased interest in affordable rapid tests, multiplex respiratory diagnostics, and resilient procurement systems. The GCC has advanced healthcare infrastructure, strong investment capacity, and extensive digital health adoption, supporting sophisticated laboratory testing, point-of-care deployment, rapid public health response capabilities, and testing strategies suited to high-mobility resident, workforce, and travel populations.

Key Country Insights for COVID-19 Testing

China has large-scale testing experience, substantial diagnostics manufacturing capacity, and continued relevance in surveillance, respiratory pathogen monitoring, and supply chain resilience. The United States has one of the most advanced COVID-19 testing ecosystems, supported by large clinical laboratory networks, at-home antigen test adoption, hospital-based molecular testing, public health surveillance, wastewater monitoring, and genomic sequencing capabilities. Japan emphasizes high-quality diagnostics, hospital-centered testing, and surveillance for respiratory infections in an aging population, while India combines large population needs with expanding domestic diagnostics manufacturing, molecular laboratory networks, and growing point-of-care access, though rural reach and affordability remain central concerns. Germany benefits from robust laboratory medicine infrastructure, high-quality molecular diagnostics, and strong clinical laboratory networks, while the United Kingdom has extensive pandemic-era testing experience, strong genomic surveillance expertise, and increasing focus on targeted testing and integrated respiratory monitoring. Australia has strong public health laboratory coordination, border-health experience, and integrated respiratory surveillance, and France maintains established public health and hospital testing systems with emphasis on surveillance, infection control, and diagnostic quality. South Korea is recognized for rapid diagnostic deployment, digital reporting, efficient public health response infrastructure, and continued readiness for COVID-19 and other emerging respiratory pathogens. Italy and Spain, both heavily affected during the early pandemic, strengthened laboratory networks and surveillance approaches and continue to prioritize hospital testing, respiratory disease differentiation, and vulnerable population protection. Canada emphasizes coordinated public health testing, laboratory quality systems, and respiratory virus surveillance, with provincial differences shaping access and prioritization. Russia has significant national laboratory capacity and public health testing infrastructure, with continued focus on domestic diagnostic capability and infectious disease monitoring. Brazil remains a major Latin American testing hub, supported by public health laboratories, academic sequencing programs, and private diagnostics, although regional disparities affect consistency of access. Mexico has expanded diagnostic capacity since the pandemic, with public and private testing channels supporting clinical diagnosis and surveillance, while access varies across regions.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize resilient, quality-assured testing platforms that can pivot between routine respiratory diagnostics and surge response. Product strategies should focus on clinically useful multiplex assays, simplified point-of-care workflows, reliable home testing support, and compatibility with digital reporting systems. Laboratories and healthcare providers should invest in automation, workforce training, biosafety, and interoperable information systems to reduce turnaround times and strengthen surveillance reporting. Diagnostic developers should maintain rigorous analytical and clinical validation, especially for emerging variants and multiplex panels, while aligning with evolving regulatory expectations. Public and private stakeholders should diversify suppliers for reagents, swabs, plastics, controls, and instruments to reduce disruption risk. Leaders should also strengthen partnerships with public health agencies, hospitals, pharmacies, and community health organizations to improve access in underserved populations. Ethical AI adoption, cybersecurity, patient privacy, and transparent data governance should be embedded into digital testing workflows. Above all, organizations should treat COVID-19 testing as part of a broader respiratory disease preparedness strategy rather than a standalone pandemic-era product category.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified public health, regulatory, scientific, and industry-relevant sources. The methodology emphasizes evidence from national and regional public health agencies, international health organizations, peer-reviewed medical literature, regulatory guidance, laboratory medicine standards, clinical diagnostic practice updates, and documented trends in testing deployment, surveillance, and technology adoption. Insights are synthesized by examining test modality evolution, regulatory changes, clinical utility, laboratory operations, regional health system capabilities, genomic surveillance activities, supply chain resilience, wastewater monitoring, point-of-care deployment, and digital health integration. The analysis avoids unverified projections and does not rely on market sizing, market share, or forecasting. Regional, group, and country insights are assessed through publicly observable healthcare infrastructure, testing policy evolution, diagnostic access, public health surveillance capacity, regulatory maturity, and pandemic preparedness indicators. The research process applies cross-validation across multiple credible sources to ensure consistency, relevance, and data-backed interpretation for strategic decision-making in COVID-19 testing.

Conclusion

COVID-19 testing has evolved from emergency mass screening into a durable pillar of respiratory disease management, outbreak preparedness, and public health surveillance. The sector's long-term relevance is supported by continued SARS-CoV-2 circulation, the need to protect high-risk populations, the clinical value of distinguishing COVID-19 from influenza and RSV, and the importance of variant monitoring. The most significant opportunities are linked to multiplex testing, decentralized access, laboratory automation, genomic surveillance, AI-enabled workflow support, and interoperable digital reporting. At the same time, stakeholders must address affordability, quality assurance, regulatory compliance, equitable access, and supply chain resilience. Organizations that integrate COVID-19 diagnostics into broader infectious disease strategies will be better positioned to support healthcare systems during seasonal surges, localized outbreaks, and future public health emergencies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. COVID-19 Testing Market, by Test Type

  • 7.1. Introduction
  • 7.2. Molecular Tests
    • 7.2.1. Single Target RT-PCR
    • 7.2.2. Multiplex RT-PCR
    • 7.2.3. Isothermal Amplification Tests
  • 7.3. Antigen Tests
    • 7.3.1. Laboratory Antigen Tests
    • 7.3.2. At Home Antigen Tests
  • 7.4. Serology Tests

8. COVID-19 Testing Market, by Sample Type

  • 8.1. Introduction
  • 8.2. Upper Respiratory Samples
    • 8.2.1. Nasopharyngeal Swab
    • 8.2.2. Oropharyngeal Swab
    • 8.2.3. Anterior Nasal Swab
  • 8.3. Lower Respiratory Samples
    • 8.3.1. Sputum
    • 8.3.2. Bronchoalveolar Lavage
    • 8.3.3. Tracheal Aspirate
  • 8.4. Saliva Samples
  • 8.5. Blood And Plasma Samples

9. COVID-19 Testing Market, by Product Type

  • 9.1. Introduction
  • 9.2. Test Kits And Reagents
    • 9.2.1. Molecular Test Kits
    • 9.2.2. Antigen Test Kits
    • 9.2.3. Serology Test Kits
    • 9.2.4. Controls And Calibrators
    • 9.2.5. Sample Preparation Reagents
  • 9.3. Services
    • 9.3.1. Laboratory Testing Services
    • 9.3.2. Outsourced Testing Services
    • 9.3.3. Data Analytics And Reporting Services

10. COVID-19 Testing Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals And Clinics
    • 10.2.1. Acute Care Hospitals
    • 10.2.2. Specialty Hospitals
    • 10.2.3. Outpatient Clinics
  • 10.3. Diagnostic Laboratories
    • 10.3.1. Independent Reference Laboratories
    • 10.3.2. Hospital Affiliated Laboratories
  • 10.4. Physician Offices
  • 10.5. Academic And Research Institutes

11. COVID-19 Testing Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. Europe
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Africa
  • 11.6. Middle East

12. COVID-19 Testing Market, by Group

  • 12.1. NATO
  • 12.2. G7
  • 12.3. BRICS
  • 12.4. European Union
  • 12.5. ASEAN
  • 12.6. GCC

13. COVID-19 Testing Market, by Country

  • 13.1. China
  • 13.2. United States
  • 13.3. Japan
  • 13.4. India
  • 13.5. Germany
  • 13.6. United Kingdom
  • 13.7. Australia
  • 13.8. France
  • 13.9. South Korea
  • 13.10. Italy
  • 13.11. Canada
  • 13.12. Russia
  • 13.13. Brazil
  • 13.14. Mexico
  • 13.15. Spain

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. 1DROP Diagnostics
  • 15.2. Abbott Laboratories
  • 15.3. ADT Biotech Sdn Bhd
  • 15.4. Aldatu Biosciences
  • 15.5. altona Diagnostics GmbH
  • 15.6. Avellino Lab USA, Inc.
  • 15.7. bioMerieux SA
  • 15.8. Co-Diagnostics, Inc.
  • 15.9. Curetis GmbH
  • 15.10. Danaher Corporations
  • 15.11. F. Hoffmann-La Roche AG
  • 15.12. GenMark Diagnostics, Inc.
  • 15.13. Hologic, Inc.
  • 15.14. Laboratory Corporation of America Holdings
  • 15.15. Luminex Corporation
  • 15.16. Mylab Discovery Solutions Pvt. Ltd.
  • 15.17. Perkin Elmer, Inc.
  • 15.18. Quidel Corporation
  • 15.19. Randox Laboratories Ltd.
  • 15.20. SD Biosensor, Inc.
  • 15.21. Seegene, Inc.
  • 15.22. Shenzhen Bioeasy Biotechnology Co., Ltd.
  • 15.23. Siemens Healthineers AG
  • 15.24. SolGent Co.,Ltd.
  • 15.25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL COVID-19 TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL COVID-19 TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL COVID-19 TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COVID-19 TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL COVID-19 TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COVID-19 TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL COVID-19 TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL COVID-19 TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL COVID-19 TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL COVID-19 TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MOLECULAR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SINGLE TARGET RT-PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SINGLE TARGET RT-PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SINGLE TARGET RT-PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLEX RT-PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLEX RT-PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLEX RT-PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ISOTHERMAL AMPLIFICATION TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ISOTHERMAL AMPLIFICATION TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ISOTHERMAL AMPLIFICATION TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIGEN TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIGEN TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIGEN TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LABORATORY ANTIGEN TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LABORATORY ANTIGEN TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LABORATORY ANTIGEN TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AT HOME ANTIGEN TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AT HOME ANTIGEN TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AT HOME ANTIGEN TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SEROLOGY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SEROLOGY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEROLOGY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL UPPER RESPIRATORY SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UPPER RESPIRATORY SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UPPER RESPIRATORY SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NASOPHARYNGEAL SWAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NASOPHARYNGEAL SWAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NASOPHARYNGEAL SWAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OROPHARYNGEAL SWAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OROPHARYNGEAL SWAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OROPHARYNGEAL SWAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTERIOR NASAL SWAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTERIOR NASAL SWAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTERIOR NASAL SWAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LOWER RESPIRATORY SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LOWER RESPIRATORY SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LOWER RESPIRATORY SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SPUTUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SPUTUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SPUTUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHOALVEOLAR LAVAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHOALVEOLAR LAVAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHOALVEOLAR LAVAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRACHEAL ASPIRATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRACHEAL ASPIRATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRACHEAL ASPIRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SALIVA SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SALIVA SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SALIVA SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD AND PLASMA SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD AND PLASMA SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD AND PLASMA SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TEST KITS AND REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TEST KITS AND REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TEST KITS AND REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MOLECULAR TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MOLECULAR TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLECULAR TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIGEN TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIGEN TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIGEN TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SEROLOGY TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SEROLOGY TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SEROLOGY TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CONTROLS AND CALIBRATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTROLS AND CALIBRATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CONTROLS AND CALIBRATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SAMPLE PREPARATION REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SAMPLE PREPARATION REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SAMPLE PREPARATION REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LABORATORY TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LABORATORY TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LABORATORY TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OUTSOURCED TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OUTSOURCED TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OUTSOURCED TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DATA ANALYTICS AND REPORTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DATA ANALYTICS AND REPORTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DATA ANALYTICS AND REPORTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE CARE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE CARE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE CARE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SPECIALTY HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SPECIALTY HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SPECIALTY HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INDEPENDENT REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INDEPENDENT REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INDEPENDENT REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITAL AFFILIATED LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITAL AFFILIATED LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOSPITAL AFFILIATED LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PHYSICIAN OFFICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHYSICIAN OFFICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PHYSICIAN OFFICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL COVID-19 TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE COVID-19 TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA COVID-19 TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL COVID-19 TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. NATO COVID-19 TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. NATO COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 204. NATO COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 205. NATO COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. NATO COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. NATO COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. NATO COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 211. G7 COVID-19 TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. G7 COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 218. G7 COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. G7 COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 221. G7 COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. G7 COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS COVID-19 TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN COVID-19 TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 263. GCC COVID-19 TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. GCC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 267. GCC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. GCC COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 269. GCC COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 270. GCC COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 272. GCC COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 273. GCC COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. GCC COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 275. GCC COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 303. JAPAN COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. JAPAN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 315. JAPAN COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 328. INDIA COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 329. GERMANY COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. GERMANY COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. GERMANY COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 332. GERMANY COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 333. GERMANY COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 342. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 343. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 345. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 349. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 351. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 352. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 355. AUSTRALIA COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 356. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 357. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 358. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 359. AUSTRALIA COVID-19 TE